Cellectis Settles Dispute over Regeneron's Use of Its Homologous Recombination Technology for up to $17.42 GEN News Highlights GEN News Highlights Regeneron Pharmaceuticalsand Cellectis have resolved a dispute between them relating to a particular use of the latters patents covering homologous recombination.Regeneron is paying $12...
PerkinElmer Creates Center to Advance Cord Blood Stem Cell Studies GEN News Highlights GEN News Highlights PerkinElmerhas established the ViaCord Research Institute (VRI) to focus on investigating potential uses of umbilical cord blood-derived stem cells.VRI will concentrate on supporting...
TopAbstracts in Sleep Disorders 07/03/2008 TopAbstracts in Sleep Disorders are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 28 days.Over 2000 peer-reviewed...
Post-doctoral paupers Everyone know's where this one is going: the salaries for post-docs (and of course grad students) in the life-sciences are low, the ones in the so-called hard-sciences only marginally higher (I am including engineering in the hard sciences...
Xceed licenses colon cancer test tech Xceed Molecular licenses gene analysis chip tech to Gen -Probe [June 4, 2008] PerkinElmer forms new stem cell research institute around ViaCord [July 3, 2008] Implant Sciences sells medical coatings biz for $750K [July 3, 2008] Genetic...
Cubist Becomes Exclusive U.S. Promotor of AstraZeneca's Anti-infection Therapy GEN News Highlights GEN News Highlights Cubist Pharmaceuticalswill exclusively promote AstraZenecas antibiotic, Merrem I.V., in the U.S.Cubist says that the agreement establishes a baseline of $20 million in annual revenues.
Cubist Becomes Exclusive U.S. Promotor of AstraZeneca's Anti-infection Therapy GEN News Highlights GEN News Highlights Cubist Pharmaceuticalswill exclusively promote AstraZenecas antibiotic, Merrem I.V., in the U.S.Cubist says that the agreement establishes a baseline of $20 million in annual revenues.
Protein that Can Predict Prostate Cancer Metastasis Identified GEN News Highlights GEN News Highlights A specific form of the protein KLF6 (KLF6-SV1) is an indicator of poor survival in men with prostate cancer, according to researchers at Mount Sinai School of Medicine.The team analyzed...
Progen Creates Subsidiary from Manufacturing Business GEN News Highlights GEN News Highlights Progen Pharmaceuticalsspun out its manufacturing business as a wholly owned subsidiary, PharmaSynth.The spin-out of the manufacturing operations is consistent with Progens core drug...
Elixir Signs License Agreement with Boston University for Use of SIRT1 Modulators GEN News Highlights GEN News Highlights Elixir Pharmaceuticalsgained an exclusive license to Boston Universitys intellectual property covering the use of modulators of SIRT1, a member of the sirtuin class of protein deacetylase...
Sciele and Addrenex Ink Second Hypertension Collaboration GEN News Highlights GEN News Highlights Sciele Pharmaand Addrenex Pharmaceuticals inked an agreement related to the latters hypertension treatment with potential in other indications.ADX415 is a centrally acting alpha...
Case Western, Copernicus Therapeutics, and Polygenix Are Recipients of $3.9M from the Ohio Department of Devel GEN News Highlights GEN News Highlights Case Western Reserve University School of Medicineand two of its spinouts, Copernicus Therapeutics and Polgenix, have landed an additional $3.9 million in funding from the Ohio Biomedical...
Lonza Reports Manufacturing Deal with Osiris and Facility Constructions GEN News Highlights GEN News Highlights Lonzasigned a clinical and commercial manufacturing agreement with Osiris Therapeutics for Prochymal, Osiris adult stem cell therapy.Prochymal is being evaluated in Phase III trials for...
Peregrine to Investigate Antiviral Applications of mAbs under $44M Deal with DoD GEN News Highlights GEN News Highlights Peregrine Pharmaceuticalswas awarded a five-year contract by the DoD worth up to $44.4 million related to treatments for viral hemorrhagic fever infections.The firm will test and develop...
Thermo Fisher Scientific Takes Over Open Biosystems GEN News Highlights GEN News Highlights Thermo Fisher Scientificis acquiring Open Biosystems to expand its position in the RNAi field.Open Biosystems specializes in shRNA and viral-vector systems for delivering shRNA into...
Qiagen Purchases Corbett Life Science for $70M GEN News Highlights GEN News Highlights Qiagenis buying Corbett Life Science for approximately $66 million in cash and $4 million in restricted Qiagen common stock.Qiagen will also pay performance and development milestone...
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Gro QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr.
Timothy J.
Holzer, Vice President, R...
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Gro QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc.(TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr.
Timothy J.
Holzer, Vice...
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Gro QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc.(TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr.
Timothy J.
Holzer, Vice...
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Gro QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc.(TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr.
Timothy J.
Holzer, Vice...
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Gro QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc.(TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr.
Timothy J.
Holzer, Vice...
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Gro QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc.(TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr.
Timothy J.
Holzer, Vice...
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Gro QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc.(TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr.
Timothy J.
Holzer, Vice...
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Gro QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc.(TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr.
Timothy J.
Holzer, Vice...
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Gro QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc.(TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr.
Timothy J.
Holzer, Vice...
